Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
muscle function
Biotech
GLD flexes muscle-wasting ambitions, launching Altagenics
GLD Partners has secured access to Heligenics’ GigaAssay platform to launch a startup with ambitions to develop muscle-wasting medicines.
Nick Paul Taylor
Oct 7, 2025 10:01am
Abcuro takes $200M series C to fund KLRG1 antibody pivotal trial
Feb 12, 2025 8:30am
Lilly, BioAge to test muscle regeneration drug with tirzepatide
Oct 26, 2023 11:39am
Chasing Big Pharma rivals, NMD posts data on rare disease drug
Oct 11, 2022 6:48am
Aeon hits phase 2 goals in rare disorder
Sep 23, 2022 11:30am
Astellas quietly cuts $450M-plus Cytokinetics R&D pact
May 3, 2021 7:15am
